TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03121742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Standard care as part of inpatient hospitalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Standard care as part of inpatient hospitalization.
Study: NCT04610242

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: skin test
Description: For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours.
Study: NCT02082067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal
Description: Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral
Description: Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic infusion
Description: Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infusion
Description: Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,75%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0,5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine 0,5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0,125%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,125%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac 30mg
Study: NCT05023902

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: Pilates has been performed to all participants two times a week in order to compare the effects of NIA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Integrative Action
Description: NIA was the experimental group of this study.
Study: NCT02082067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulong sono, Pajunk, Germany

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stimulong sono, Pajunk, Germany
Study: NCT00667758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 3-5 mg s.c. on days 1-5
Study: NCT03193437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Selinexor
Description: Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
Study: NCT03918408

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study: NCT02819661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
Study: NCT03170739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine given during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine given during surgery.
Study: NCT03076645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator support and education
Description: Group engaged with facilitator support and education
Study: NCT02819661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intrathecal morphine
Description: is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intrathecal morphine
Description: is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intrathecal morphine
Description: is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intrathecal morphine
Description: is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
Study: NCT00667758

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3-5 ml NaCl s.c. on days 1-5
Study: NCT01651130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
Study: NCT03660371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV/MP
Description: Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV without MP
Description: No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
Study: NCT00591227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.
Study: NCT00130208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: 100 mg sulodexide gelcaps

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg gelcap
Study: NCT04015297

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: raman analysis
Description: negative or pozitive

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: raman analysis
Description: negative or pozitive
Study: NCT02942810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5222
Description: IV infusion over a period of 60 minutes
Study: NCT02920476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest
Study: NCT05092035

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: single high-fidelity expiratory CO2 analysis
Description: in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: single high-fidelity expiratory CO2 analysis
Description: in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: single high-fidelity expiratory CO2 analysis
Description: in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: single high-fidelity expiratory CO2 analysis
Description: in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
Study: NCT02119637

Intervention type: DEVICE
Intervention: Transcranial magnetic stimulation (TMS)
Description: 1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.

Intervention type: DEVICE
Intervention: Transcranial magnetic stimulation (TMS)
Description: 1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.

Intervention type: DEVICE
Intervention: MRI
Description: Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement

Intervention type: DEVICE
Intervention: MRI
Description: Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
Study: NCT00635687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: transient elastography measure - Liver stiffness
Study: NCT02683291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 30mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 30mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
Study: NCT01581892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
Study: NCT04540068

Intervention type: DRUG
Intervention: Transforaminal Epidural Injection
Description: Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.

Intervention type: DRUG
Intervention: Transforaminal Epidural Injection
Description: Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
Study: NCT00307723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Monday through Friday ending on day 38 of cycle 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Monday through Friday ending on day 38 of cycle 1
Study: NCT01534754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine plus Lactobacillus casei
Description: Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesalazine placebo plus Lactobacillus casei placebo
Description: Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 800 mg
Description: Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus casei
Description: Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
Study: NCT03797196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose tacrolimus in combination with everolimus
Description: a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose tacrolimus with mycophenolate mofetil
Description: A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
Study: NCT03057535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Study: NCT02599662

Intervention type: RADIATION
Group type: OTHER
Intervention: 10 Gy Low-KV IORT
Description: : intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.

Intervention type: RADIATION
Group type: OTHER
Intervention: 15 Gy Low-KV IORT
Description: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.

Intervention type: RADIATION
Group type: OTHER
Intervention: 20 GY Low-KV IORT
Description: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
Study: NCT01633307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Teaching program
Study: NCT01220960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: art therapy
Description: Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
Study: NCT02836587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
Study: NCT06352762

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions. An additional 30 minutes of robotic rehabilitation was applied to the conventional physiotherapy program. Robotic rehabilitation was applied after each session of conventional physiotherapy applications.
Study: NCT02725515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb5871
Study: NCT03918408

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study: NCT02725515

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match XmAb5871